Taysha Gene Therapies, Inc.

TSHANASDAQHealthcare● Active

$5.43

$-0.07(-1.27%)

Market Cap$1.4B

P/E Ratio—

52W High$7.3

52W Low$2.25

Avg Volume2.7M

Open$5.60

Beta1.18

Insider Trades Ownership Employees

Taysha Gene Therapies, Inc. (TSHA) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · TSHA · as of Jun 8, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.00

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 0%Active transactions only · RSU vesting excluded100% Sell ↓

Taysha Gene Therapies, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 8, 2026

TSHA insider buying and selling by quarter

TSHA insider selling · TSHA insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

5.3M2.6M0

2024 Q1

2024 Q2

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 8, 2026

Active insiders

Most active in past 12 months · TSHA ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

TSHA executive sell shares · TSHA board member insider trading · TSHA insider trading SEC filing

Showing 60 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
Jun 1, 2026	Stalfort John A III Director	Award	21,335	—	—	1,176,559	Form 4
Jun 1, 2026	Donenberg Phillip B. Director	Award	21,335	—	—	241,289	Form 4
Jun 1, 2026	Long Alison S Director	Award	21,335	—	—	127,178	Form 4
Jun 1, 2026	Sepp-Lorenzino Laura Director	Award	21,335	—	—	127,178	Form 4
Apr 10, 2026	Nagendran Sukumar President and Head of R&D · Director	Option	19,021	$1.71	$33K	1,336,410	Form 4
Apr 10, 2026	Nagendran Sukumar President and Head of R&D · Director	Sale	200,000	$4.46	$892K	1,136,410	Form 4
Feb 4, 2026	Alam Kamran CHIEF FINANCIAL OFFICER	Sale	1,655	$4.52	$7K	1,442,131	Form 4
Jan 23, 2026	Nagendran Sukumar President and Head of R&D · Director	Sale	89,132	$4.75	$423K	1,344,307	Form 4
Jan 26, 2026	Nagendran Sukumar President and Head of R&D · Director	Sale	26,918	$4.61	$124K	1,317,389	Form 4
Jan 23, 2026	Nolan Sean P. CEO · Director	Sale	136,789	$4.75	$650K	2,949,569	Form 4
Jan 26, 2026	Nolan Sean P. CEO · Director	Sale	41,312	$4.61	$190K	2,908,257	Form 4
Jan 23, 2026	Alam Kamran CHIEF FINANCIAL OFFICER	Sale	78,968	$4.75	$375K	1,467,635	Form 4
Jan 26, 2026	Alam Kamran CHIEF FINANCIAL OFFICER	Sale	23,849	$4.61	$110K	1,443,786	Form 4
Jan 12, 2026	Alam Kamran CHIEF FINANCIAL OFFICER	Award	359,000	—	—	1,546,603	Form 4
Jan 12, 2026	Nolan Sean P. CEO · Director	Award	1,008,000	—	—	3,086,358	Form 4
Jan 12, 2026	Nagendran Sukumar President and Head of R&D · Director	Award	427,000	—	—	1,433,439	Form 4
Jan 12, 2026	Nagendran Sukumar President and Head of R&D · Director	Option	88,676	$1.71	$152K	1,206,439	Form 4
Jan 12, 2026	Nagendran Sukumar President and Head of R&D · Director	Option	111,324	$0.70	$78K	1,117,763	Form 4
Jan 12, 2026	Nagendran Sukumar President and Head of R&D · Director	Sale	200,000	$4.71	$942K	1,006,439	Form 4
Dec 1, 2025	Nagendran Sukumar President and Head of R&D · Director	Option	260,047	$1.71	$445K	1,266,486	Form 4
Nov 28, 2025	Nagendran Sukumar President and Head of R&D · Director	Option	39,953	$1.71	$68K	1,116,564	Form 4
Nov 28, 2025	Nagendran Sukumar President and Head of R&D · Director	Option	70,172	$0.70	$49K	1,076,611	Form 4
Nov 28, 2025	Nagendran Sukumar President and Head of R&D · Director	Sale	110,125	$4.75	$523K	1,006,439	Form 4
Dec 1, 2025	Nagendran Sukumar President and Head of R&D · Director	Sale	260,047	$4.51	$1.17M⚡	1,006,439	Form 4
Sep 10, 2025	Nagendran Sukumar President and Head of R&D · Director	Option	41,150	$0.70	$29K	1,206,439	Form 4

Stalfort John A III

Director

Award

Date

Jun 1

21,335

Price

—

Value

—

View Form 4 on SEC.gov

Donenberg Phillip B.

Director

Award

Date

Jun 1

21,335

Price

—

Value

—

View Form 4 on SEC.gov

Long Alison S

Director

Award

Date

Jun 1

21,335

Price

—

Value

—

View Form 4 on SEC.gov

Sepp-Lorenzino Laura

Director

Award

Date

Jun 1

21,335

Price

—

Value

—

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Apr 10

19,021

Price

$1.71

Value

$33K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Apr 10

200,000

Price

$4.46

Value

$892K

View Form 4 on SEC.gov

Alam Kamran

CHIEF FINANCIAL OFFICER

Sale

Date

Feb 4

1,655

Price

$4.52

Value

$7K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Jan 23

89,132

Price

$4.75

Value

$423K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Jan 26

26,918

Price

$4.61

Value

$124K

View Form 4 on SEC.gov

Nolan Sean P.

CEO · Director

Sale

Date

Jan 23

136,789

Price

$4.75

Value

$650K

View Form 4 on SEC.gov

Nolan Sean P.

CEO · Director

Sale

Date

Jan 26

41,312

Price

$4.61

Value

$190K

View Form 4 on SEC.gov

Alam Kamran

CHIEF FINANCIAL OFFICER

Sale

Date

Jan 23

78,968

Price

$4.75

Value

$375K

View Form 4 on SEC.gov

Alam Kamran

CHIEF FINANCIAL OFFICER

Sale

Date

Jan 26

23,849

Price

$4.61

Value

$110K

View Form 4 on SEC.gov

Alam Kamran

CHIEF FINANCIAL OFFICER

Award

Date

Jan 12

359,000

Price

—

Value

—

View Form 4 on SEC.gov

Nolan Sean P.

CEO · Director

Award

Date

Jan 12

1,008,000

Price

—

Value

—

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Award

Date

Jan 12

427,000

Price

—

Value

—

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Jan 12

88,676

Price

$1.71

Value

$152K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Jan 12

111,324

Price

$0.70

Value

$78K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Jan 12

200,000

Price

$4.71

Value

$942K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Dec 1

260,047

Price

$1.71

Value

$445K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Nov 28

39,953

Price

$1.71

Value

$68K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Nov 28

70,172

Price

$0.70

Value

$49K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Nov 28

110,125

Price

$4.75

Value

$523K

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Sale

Date

Dec 1

260,047

Price

$4.51

Value

$1.17M ⚡

View Form 4 on SEC.gov

Nagendran Sukumar

President and Head of R&D · Director

Option

Date

Sep 10

41,150

Price

$0.70

Value

$29K

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About TSHA insider trading

TSHA insider trades

Taysha Gene Therapies, Inc. (TSHA) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Nagendran Sukumar (President and Head of R&D · Director), Alam Kamran (CHIEF FINANCIAL OFFICER), Nolan Sean P. (CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. TSHA insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Taysha Gene Therapies, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

TSHA insider trading · 5 questions

The insiders of Taysha Gene Therapies, Inc. (TSHA) include executives and directors such as Nagendran Sukumar (President and Head of R&D · Director), Alam Kamran (CHIEF FINANCIAL OFFICER), Nolan Sean P. (CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

TSHA board member insider tradingwho are TSHA insidersTSHA insider rosterTaysha Gene Therapies, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026